Abstracts tagged "heart disease and rheumatoid arthritis (RA)"

Abstract Number: 1032 • 2017 ACR/ARHP Annual Meeting
Trends in Hospitalizations Following Heart Failure Diagnosis in Rheumatoid Arthritis
Elena Myasoedova¹, Eric L. Matteson², Sara J. Achenbach³, John M. Davis III⁴, Soko Setoguchi⁵, Sherine E. Gabriel⁶ and Cynthia S. Crowson⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rutgers School of Public Health, New Brunswick, NJ, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The rising prevalence of heart failure (HF) in the general population and associated increased hospitalization costs is a major public health problem. There is…
Abstract Number: 2168 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Myocardial Infarction Among Rheumatoid Arthritis Patients
Uyen Sa D.T. Nguyen¹, Yuqing Zhang², Na Lu³, Jingbo Niu⁴, David T. Felson⁴, Michael P. Lavalley⁵, Jeffrey A. Sparks⁶, Shun-Chiao Chang⁷, Elizabeth W. Karlson⁸ and Hyon K. Choi³, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Biostatistics, Boston University, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Smoking is a strong risk factor for myocardial infarction (MI), but not among rheumatoid arthritis (RA) patients. These paradoxical findings may be due to…
Abstract Number: 2597 • 2015 ACR/ARHP Annual Meeting
Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, Afshin Zartoshti⁴, WH Robinson⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Heart failure (HF) is a leading cause of excess deaths in RA. We previously found an association between left ventricular mass index (LVMI) and…
Abstract Number: 2892 • 2014 ACR/ARHP Annual Meeting
The Relative Risk of Incident NON-Ischemic Heart Failure in Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist², Johan Askling³, Lars Lund⁴ and Daniel Andersson⁵, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, ²Karolinska Institutet, Unit of Clinical Epidemiology, Department of medicine, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Unit of Cardiology section for Heart Failure. Department of Medicine, Stockholm, Sweden, ⁵Karolinska Institutet, Unit of Cardiology section for heart failure. Department of Medicine, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) may be at increased risk of developing heart failure (HF). Inflammatory activity has been linked to the pathogenesis of…
Abstract Number: 945 • 2014 ACR/ARHP Annual Meeting
Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy
Thomas Schau¹, Michael Gottwald², Christian Butter¹ and Michael Zaenker³, ¹Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, ²Internal Med. Dept., Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany
Background/Purpose Risk of heart failure (HF) is increased in patients with RA, however there is great variance in reported prevalence rates due to different diagnostic…
Abstract Number: 366 • 2013 ACR/ARHP Annual Meeting
Traditional Cardiac Risk Factors Predict Significant Coronary Plaque Burden In Asymptomatic Patients With Rheumatoid Arthritis
George A. Karpouzas¹, Jennifer Malpeso², Tae-Young Choi², Youngju Pak³ and Matthew Budoff², ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ³Biostatistics, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Computed tomography angiography (CTA) provides prognostic information in patients with suspected but unknown coronary artery disease (CAD); subjects without plaque had no incident major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].